PE20150935A1 - Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio - Google Patents

Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio

Info

Publication number
PE20150935A1
PE20150935A1 PE2015000220A PE2015000220A PE20150935A1 PE 20150935 A1 PE20150935 A1 PE 20150935A1 PE 2015000220 A PE2015000220 A PE 2015000220A PE 2015000220 A PE2015000220 A PE 2015000220A PE 20150935 A1 PE20150935 A1 PE 20150935A1
Authority
PE
Peru
Prior art keywords
tablet formulation
irbesartan
magnesium carbonate
composite tablet
layer composite
Prior art date
Application number
PE2015000220A
Other languages
English (en)
Inventor
Yong Il Kim
Jung Hyun Cho
Jun Young Choi
Young Keun Choi
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20150935A1 publication Critical patent/PE20150935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere a una formulacion de comprimido compuesto de dos capas que comprenden (a) una primera capa que comprenden irbesartan o una de sus sales aceptables desde el punto de vista farmaceutico; y (b) una segunda capa que comprenden atorvastatina o una de sus sales aceptables desde el punto de vista farmaceutico y carbonato de magnesio (MgCO3) en una proporcion en peso de 1:4 hasta 1:5, y un metodo para la preparacion de los mismos. Al exhibir excelentes velocidades de disolucion y biodisponibilidad, la formulacion de comprimido compuesto de dos capas es util como agente terapeutico para la hipertension y la hipercolesterolemia
PE2015000220A 2012-08-31 2013-08-30 Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio PE20150935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제

Publications (1)

Publication Number Publication Date
PE20150935A1 true PE20150935A1 (es) 2015-06-20

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000220A PE20150935A1 (es) 2012-08-31 2013-08-30 Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio

Country Status (31)

Country Link
US (1) US20150209290A1 (es)
EP (1) EP2890368A4 (es)
JP (1) JP6363079B2 (es)
KR (1) KR20140028971A (es)
CN (1) CN104602677A (es)
AR (1) AR092386A1 (es)
AU (1) AU2013309686B2 (es)
BR (1) BR112015004471A8 (es)
CA (1) CA2882735A1 (es)
CL (1) CL2015000402A1 (es)
CR (1) CR20150115A (es)
DO (1) DOP2015000040A (es)
EA (1) EA030306B1 (es)
EC (1) ECSP15010600A (es)
GT (1) GT201500043A (es)
IL (1) IL237424A0 (es)
IN (1) IN2015DN01463A (es)
MA (1) MA37951B2 (es)
MX (1) MX354800B (es)
MY (1) MY175897A (es)
NI (1) NI201500027A (es)
NZ (1) NZ706472A (es)
PE (1) PE20150935A1 (es)
PH (1) PH12015500394A1 (es)
RU (1) RU2015111546A (es)
SG (1) SG11201500584YA (es)
TW (1) TWI651101B (es)
UA (1) UA115995C2 (es)
UY (1) UY35001A (es)
WO (1) WO2014035188A1 (es)
ZA (1) ZA201502156B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
CR20190577A (es) * 2017-07-17 2020-01-29 Lilly Co Eli Composiciones farmacéuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
PE20030324A1 (es) 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
KR20090114325A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
JP5534004B2 (ja) * 2010-03-29 2014-06-25 アステラス製薬株式会社 口腔内崩壊錠
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
ECSP15010600A (es) 2015-12-31
AU2013309686B2 (en) 2017-09-07
AR092386A1 (es) 2015-04-22
CA2882735A1 (en) 2014-03-06
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
JP6363079B2 (ja) 2018-07-25
AU2013309686A1 (en) 2015-02-26
WO2014035188A1 (en) 2014-03-06
PH12015500394A1 (en) 2015-04-27
BR112015004471A8 (pt) 2019-08-27
EA201590469A1 (ru) 2015-06-30
IL237424A0 (en) 2015-04-30
UY35001A (es) 2014-03-31
KR20140028971A (ko) 2014-03-10
JP2015530384A (ja) 2015-10-15
GT201500043A (es) 2017-08-24
EA030306B1 (ru) 2018-07-31
BR112015004471A2 (pt) 2017-07-04
NZ706472A (en) 2018-02-23
US20150209290A1 (en) 2015-07-30
MY175897A (en) 2020-07-14
EP2890368A1 (en) 2015-07-08
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
ZA201502156B (en) 2016-07-27
MX2015002526A (es) 2015-06-23
CN104602677A (zh) 2015-05-06
IN2015DN01463A (es) 2015-07-03
MX354800B (es) 2018-03-22
DOP2015000040A (es) 2015-04-15
TWI651101B (zh) 2019-02-21
MA37951B2 (fr) 2019-12-31
RU2015111546A (ru) 2016-10-20
NI201500027A (es) 2017-01-04
EP2890368A4 (en) 2016-03-02
SG11201500584YA (en) 2015-02-27
CL2015000402A1 (es) 2015-06-05

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO6592025A2 (es) Fomulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg -coa recutasa e irbesartan
PE20140163A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
ECSP15010617A (es) Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invención
PE20150935A1 (es) Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio
MX2016007741A (es) Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol.
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.
PE20150022A1 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
TH155663A (es)
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
CO6280050A1 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa
MX352778B (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
DOP2011000238A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antinflamatorio, no esteroideo y un derivado de colchicosido
CR20110394A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antiinflamatorio, no esteroideo y un derivado de colchicosido

Legal Events

Date Code Title Description
FD Application declared void or lapsed